Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Meteor 1: Pemrametostat in Advanced Solid Tumors and NHL
NCT02783300Phase 1Completed
- Sponsor
- GSK
- Start
- Aug 2016
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label trial of pemrametostat in solid tumor, non-Hodgkin lymphoma (NHL), triple-negative breast cancer (TNBC) and 6 more (3 arms), sponsored by GSK. Primary endpoints: Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs) up to 42 months, Number of Participants Withdrawn Due to AEs up to 42 months and 4 more. Started Aug 2016; status: completed.
02
Drugs
pemrametostat
03
Conditions
solid tumornon-Hodgkin lymphoma (NHL)triple-negative breast cancer (TNBC)transitional cell carcinoma (TCC)glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT02783300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02783300.